To help extend its cash runway into mid-2026 and further development of a key asset, Mersana Therapeutics is letting go of about 55% of its workforce, the company announced May 6. Mersana, which is developing antibody-drug conjugates targeting cancers of high unmet medical need, expects to mostly complete the cuts by the end of the third quarter.